Methods of Treating Giardiasis Using Food and Drug Administration-Approved Compounds
Lead Inventor: Wei Zheng (NCATS)
Inventors: Christopher Austin (NCATS), Catherine Chen (NCATS), Andrey Galkin (University of Maryland), Osnat Herzberg (University of Maryland Biotechnology Institute), Liudmila Kulakova (University of Maryland), Juan Marugan (NCATS), Noel Southall (NCATS)
Ref. No.: E-211-2010/1
Abstract: This technology includes a group of at least twenty-nine, diverse, commercially available compounds that are newly identified for activity against Giardia lamblia parasites. At least six of the candidate compounds, Bortezomib, Decitabine, Hydroxocobalamin, Amlexanox, Idarubicin, and Auranofin have pre-existing FDA approval for human use for other (non-Giardia) conditions. Another three compounds, Fumagillin, Nitarsone and Carbadox have preexisting approval for veterinary use for non-Giardia conditions. Additional active compounds identified include: Acivicin, Riboflavin butyrate, BTO-1, GW9662, Dinitroph-dfgp, Deserpidine, Tetramethylthiuram disulsulfide, Disulfiram, Mitoxantrone, Ecteinascidin 743, 17-allyaminogeldanamycin, Carboquone and Nocodazole. The anti-Giardial activity of these compounds presents a cost saving opportunity for the rapid development of new, better tolerated treatments for the most prevalent human intestinal parasite infection in the United States and the world.
High-Throughput Giardia Lamblia Viability Assay Using Bioluminescent ATP Content Measurements • Antimicrobial Agents and Chemotherapy • February 2011 • Probe Development Branch, NCATS Chemical Genomics Center